Webstar Technology Group Inc (WBSR): Anybody hearing anything on eco, origina...

Anybody hearing anything on eco, original plan was

w6w9t8015 · 2025-02-05T15:53:43.9400000Z

Anybody hearing anything on eco, original plan was to give shares to original wbsr shareholders, ,nothing happened, my guess just keeps it private,

Play Episode

6min

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

CleanSpace eyes 30% growth, EBITDA breakeven

CleanSpace Holdings Ltd CEO Gabrielle O’Carroll talked with Proactive about AIM's Small and Midcap Conference about the company’s growth trajectory and product innovation in powered air purifying respirators (PAPRs). CleanSpace was founded in 2009, based on an innovation developed during the SARS epidemic. The company's differentiator is its lightweight, head-mounted respirators that contrast with the bulkier waist-mounted models commonly available in the industrial market. “We are steadily approaching that breakeven EBITDA, profitable EBITDA position, which is our goal,” O’Carroll said. O’Carroll explained that CleanSpace's respirators are well suited for industrial sectors like mining, infrastructure, and petrochemicals. The products are marketed in key regions including the United States, Western Europe, and Australia. The company has 52 employees and recorded AU$9.2 million in revenue in the first half, up 26% year-over-year. CleanSpace is targeting annual revenue growth of 25–30% and expects to achieve positive EBITDA soon. To drive this, the company is focused on raising brand awareness, engaging directly with end users, and supporting occupational hygienists and safety managers. CleanSpace is also investing in R&D to support future product launches. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #CleanSpaceHoldings #IndustrialSafety #RespiratoryProtection #PAPR #WorkplaceSafety #OccupationalHealth #ASXStocks #HealthTech #EBITDA #MiningSafety #InfrastructureSafety #ProactiveInvestors

Proactive - Interviews for investors

Sprintex secures A$3.25m to expand global output; reduce debt

Sprintex Ltd (ASX:SIX) managing director and CEO Jay Upton talked with Proactive's Stephen Gunnion about the company’s successful A$3.25 million capital raise, drawing strong backing from both existing shareholders and new institutional investors. Upton said approximately A$1.5 million of the funds would go toward debt reduction, with the remaining A$1.75 million allocated to accelerating production and sales of Sprintex’s new range of high-speed electric compressors. These products aim to improve energy efficiency, offering “more than 50% energy savings versus the current benchmark products”. He discussed the company’s strategic manufacturing expansion, highlighting the transition of its Malaysian facility to support electric compressor production—mirroring current operations in Suzhou, China. This move is designed to double manufacturing capacity, navigate global trade sensitivities, and better serve regional preferences. Currently in the Netherlands, Upton also outlined a five-year partnership with Mest Water, a Dutch wastewater treatment firm focused on ammonia reduction in livestock manure—a project supported by the Dutch government. Sprintex will supply compressors for this initiative. Looking ahead, Sprintex is set to exhibit at the Hannover International Trade Fair in Germany, where the company expects to attract significant attention for its clean air and vacuum solutions across industries like aquaculture, semiconductors, textiles, and agriculture. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #Sprintex #CleanTech #IndustrialCompressors #EnergyEfficiency #GreenTechnology #CapitalRaise #Manufacturing #DutchTech #HannoverFair #VacuumTechnology #AsiaManufacturing #SustainableIndustry #AmmoniaReduction #ElectricCompressors

Proactive - Interviews for investors

EBR Systems nears FDA approval for CRT pacemaker

EBR Systems Inc Senior Vice President Andrew Shute talked with Proactive at the AIM maSmall and Midcap Conference about the company’s upcoming FDA decision for its leadless CRT pacemaker system. The device is designed to treat heart failure and represents the only leadless option in a market currently dominated by three players—with no direct competitor. Shute said, “We've developed the world's only leadless pacemaker to treat heart failure. And we're on track to receive FDA approval within the next two and a half weeks.”* The product already holds FDA Breakthrough Device designation, and has shown strong clinical results, including a 16.4% reduction in left ventricular end systolic volume—well above the target goal of 9.3%. Shute outlined the company's go-to-market plan, emphasizing that reimbursement is expected to begin from October 1st under the NTAP and TPT schemes, enabling an ASP of USD 45,000. The company only needs to sell around 2,200 units annually to reach USD 100 million in revenue. “We’ve got no direct competition,” he said. He also highlighted the successful completion of the FDA’s pre-approval inspection with no observations—an uncommon achievement in the medical device industry. The device, supported by data published in JAMA Cardiology, was also featured at the Heart Rhythm Society meeting in 2023. During the interim, the US commercial team will establish purchasing agreements, prepare technology committee engagements, and begin physician training for a limited market release. #EBRSystems #MedicalDevices #HeartFailureTreatment #LeadlessPacemaker #CardiacTech #FDAApproval #CRTDevice #InvestingInHealthcare #BreakthroughDevice #MedTechInnovation #JAMACardiology #HeartRhythmSociety

Followers	62
Posts	8449
Boards Moderated	0
Alias Born	07/16/2008

Volume:	-
Day Range:
Bid:	0.045
Ask:	0.049
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

WBSR Detailed Quote

Recent WBSR News

More WBSR News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent WBSR News

Go Ad-Free